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1. Welcome to this special issue of AJPS on
inhalation drug delivery
On behalf of Inhalation Asia 2015 (IA15), we are delighted to
bring to you this special issue on Inhalation Drug Delivery pub-
lished by the Asian Journal of Pharmaceutical Sciences.
The special issue is published to coincide with the 2nd net-
working event of Inhalation Asia, the leading network of
professionals in inhalation drug delivery in Asia (www
.inhalationasia.org). Inhalation Asia 2015 took place from 9 to
11 September 2015 at the Shenyang Pharmaceutical Univer-
sity in Shenyang, PR China.
2. Inhalation Asia 2015
This 2nd edition of Inhalation Asia hosted 150 delegates from
East and West and fulfilled its ambition to connect scientists
and technologists working on inhalation drug delivery in the
Asian region and beyond.
The inhalation drug delivery community in the Austral-
Asian regions is growing in numbers. New companies dedicating
themselves to innovation in inhalation drug delivery start every
month, and a number of academic centers are now well es-
tablished in Shenyang, Beijing or Shanghai, Hong Kong,Taipei,
Singapore, Otago, Tokyo, Seoul, Sydney, Melbourne, Mumbai.
We were pleased to welcome many scientists and industrial-
ists to the event.
3. IA15: a packed program
To our great pleasure, many of the world leading scientists in
inhalation drug delivery accepted to present their recent re-
search achievements and share their cutting-edge views. The
program of IA15 was packed: from traditional lectures to dis-
cussions on early phase work during the poster sessions, the
autumn school or the learn and brush-up of 2 workshop ses-
sions. The program of IA15 was tailored to capture the
particularity of the Asian inhalation world. Its focus and dy-
namics are different in some ways from the EU or US markets,
yet call upon similar knowledge and technologies to achieve
similar aims: improved therapies for lung disease.The 6 main
sessions of IA15 covered the following topics: product devel-
opment, pharmaceutical sciences, e-cigarettes, lung cancer
therapies, treatments for tuberculosis and how to bring fin-
ished products on different markets. All the posters and
presentations of the event are available on our website at
www.inhalationasia.org.
4. The AJPS special issue
Inhalation drug delivery in such a vast region as Asia is not
at the same stage of development in every country. Japan’s
inhaled therapies are well established and driven mostly by
brand products. All major pharmaceutical companies have
inhaled products approved and on sale in Japan. Dry powder
inhalers are particularly strong in Japan, with the world’s only
nasal dry powder inhaler being marketed there. Next in terms
of maturity is India. There is a plethora of inhaled products
manufactured and marketed in India.These are mostly generic
products for the local market. India’s expertise is primarily about
APIs; finished products manufacturing stems from this exper-
tise. Along with India, China is a well established supplier of
APIs; what is lesser known to the outside world is that China
has been fostering development in inhaled finished dosage
forms for a couple of years, particularly with a view to effect
the CFC to HFA transition for pMDI. Nebulisers are the pre-
ferred route of treatment for lung disease in China, but local
pMDI products are being developed, and the CFDA is leading
discussions on leachable and extractable in this context. DPIs
are only in their infancy in China, at least for locally manu-
factured products, but China is known for the speed at which
it embraces change, and local DPI products could well be ready
sooner than is currently anticipated. Taiwan has manufactur-
ing facilities for pMDIs and other inhaled products, alongside
its API business. They are engaged mostly in generic prod-
ucts but have branded ambitions. Korea is a new starter in this
field, local pharmaceutical companies are entering the market
via generics but some already have brand pipelines. Singa-
pore has been a hub for services to the pharmaceutical industry
for a while, but no national champion has emerged yet for
inhaled therapies, despite active academic centers. Malaysia
is building up its respiratory industry: it is rumored that they
are working in collaboration with Bangladesh, which has a
generic industry with inhalation production facilities. Further
afield in Asia,Turkey has world leading companies with inhaled
marketed products.The inhalation industries in other very large
countries such as Indonesia, Pakistan or the Philippines are
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to this date inexistent or embryonic.The situation in the Middle
East is more fluid and will be worth watching over the next
few years.
The major limits to the expansion of inhalation
industry in Asia are i) the maturity of market, ii) acceptance
of the inhaled route as a viable route of medicine delivery, iii)
lack of healthcare schemes, iv) the costs of medicines, v)
lack of scientific ecosystems capable of innovation and
problem solving, vi) inadequate quality assurance culture and
implementation (let us not forget that in 2015 the EMA with-
drew the marketing authorisations of 400 pharmaceutical
products manufactured in India), and vii) a lack of a consis-
tent and clear regulatory framework for medicine approvals
in many of these markets. The lack of inhaled therapies
is certainly not due to a lack of patients who would
benefit greatly from treatments against asthma, COPD or
tuberculosis.
In this special issue of AJPS we have tried to shed light on
these manymarkets and their characteristics selected from the
talks and posters presented at IA15. This special issue of AJPS
on inhalation drug delivery is a snapshot of the talks and
posters presented at IA15; 10 of the presenters were selected
to publish their work in manuscripts that we are pleased to
have gathered in this journal issue.The diversity of the topics
in this special issue is a good testimony of the diversity of the
inhalation field.
Parisini et al. in their modelling work demonstrate how the
agglomeration process of blended particles can be fitted with
classical equations; YongHong Liao et al. contribute to the un-
derstanding of HFA formulations with their work on particle
surface morphology and pMDI performance; Bing Zhu et al. for-
mulate theophylline as a DPI and evidence the efficacy of the
formulation in vitro in cell models; Satu Lakio et al. prepare
DPI formulations of amino acid L arginine and stress test them
in very humid environment similar to those encountered in
many Asian countries; HaoYing Li et al. prepare aztreonam-
amino acid DPI formulations in the search for anti-tuberculosis
therapies; the fight against tuberculosis is a very real concern
in Asia, and Suresh et al. give another example of anti-
tuberculosis therapies in their work with rifampicin lipospheres;
e-cigarettes were invented in China, Cipolla et al. pick up on
this topic on their paper on nicotine therapies; therapies against
lung cancer are reviewed byWingHin Lee et al.; Shuguang Hou
et al. give us an insight in the regulatory requirements for
inhaled products across jurisdictions; Ducharme et al. chal-
lenge the status quo on inhaled bioequivalence studies with
powerful arguments on bio markers is the necessity of PD
studies.
We are most grateful to the authors and reviewers who gave
their time and their talent to write articles of high quality and
contribute to the debate on inhaled therapies.
5. Inhalation Asia is more than a conference
Inhalation Asia is an open community of scientists and prac-
titioners; it is a unique opportunity for all of us to meet in
person, network with each other and showcase our ideas, re-
search, products, and materials.
Inhalation Asia lives beyond its 3 day event every 2 years.
You can follow us on our website, on LinkedIn, on Twitter and
WeChat. Thanks to all of your efforts, support and creativity,
we have been able to federate a lively online community,
making Inhalation Asia more active and fun every day.
Inhalation Asia is committed to open access to the confer-
ence materials, abstracts, lectures and posters. All practitioners
in the field of inhalation drug delivery can access the confer-
ence materials as long as they are registered users on the IA
website (www.inhalationasia.org). AJPS is also an open-
access journal, and we are pleased to be associated with them.
We hope you will enjoy this special issue we edited.
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